Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Details
Publication Year 2023-08,Volume 129,Issue #2,Page 309-317
Journal Title
British Journal of Cancer
Publication Type
Research article
Abstract
BACKGROUND: GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK3368715 in adults with advanced-stage solid tumors. METHODS: In part 1, escalating doses of oral once-daily GSK3368715 (50, 100, and 200 mg) were evaluated. Enrollment was paused at 200 mg following a higher-than-expected incidence of thromboembolic events (TEEs) among the first 19 participants, resuming under a protocol amendment starting at 100 mg. Part 2 (to evaluate preliminary efficacy) was not initiated. RESULTS: Dose-limiting toxicities were reported in 3/12 (25%) patients at 200 mg. Nine of 31 (29%) patients across dose groups experienced 12 TEEs (8 grade 3 events and 1 grade 5 pulmonary embolism). Best response achieved was stable disease, occurring in 9/31 (29%) patients. Following single and repeat dosing, GSK3368715 maximum plasma concentration was reached within 1 h post dosing. Target engagement was observed in the blood, but was modest and variable in tumor biopsies at 100 mg. CONCLUSION: Based on higher-than-expected incidence of TEEs, limited target engagement at lower doses, and lack of observed clinical efficacy, a risk/benefit analysis led to early study termination. TRIAL REGISTRATION NUMBER: NCT03666988.
Publisher
Springer Nature
Keywords
Adult; Humans; *Antineoplastic Agents/adverse effects; Enzyme Inhibitors/adverse effects; Maximum Tolerated Dose; *Neoplasms/pathology; Treatment Outcome
Department(s)
Medical Oncology
PubMed ID
37237172
Open Access at Publisher's Site
https://doi.org/10.1038/s41416-023-02276-0
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-14 03:09:10
Last Modified: 2023-09-14 03:09:44

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙